Search Results - Plotkin, Scott

Refine Results
  1. 1
    Chemoprevention for neurofibromatosis 2: just over the horizon?

    Chemoprevention for neurofibromatosis 2: just over the horizon? by Plotkin, Scott R.

    Published 2014
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  2. 2
    Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis

    Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis by Blakeley, Jaishri O., Plotkin, Scott R.

    Published 2016
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  3. 3
    Whole Body MRI at 3T with Quantitative Diffusion Weighted Imaging and Contrast-Enhanced Sequences for the Characterization of Peripheral Lesions in Patients with Neurofibromatosis Type 2 and Schwannomatosis

    Whole Body MRI at 3T with Quantitative Diffusion Weighted Imaging and Contrast-Enhanced Sequences for the Characterization of Peripheral Lesions in Patients with Neurofibromatosis... by Fayad, Laura M., Blakeley, Jaishri, Plotkin, Scott, Widemann, Brigitte, Jacobs, Michael A.

    Published 2013
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  4. 4
    ACTR-36. A SINGLE ARM PHASE 2 STUDY OF THE DUAL mTORC1/mTORC2 INHIBITOR VISTUSERTIB PROVIDED ON AN INTERMITTENT SCHEDULE FOR NEUROFIBROMATOSIS 2 PATIENTS WITH PROGRESSIVE OR SYMPTOMATIC MENINGIOMAS

    ACTR-36. A SINGLE ARM PHASE 2 STUDY OF THE DUAL mTORC1/mTORC2 INHIBITOR VISTUSERTIB PROVIDED ON AN INTERMITTENT SCHEDULE FOR NEUROFIBROMATOSIS 2 PATIENTS WITH PROGRESSIVE OR SYMPTO... by Plotkin, Scott, Jordan, Justin, Beauchamp, Roberta, Muzikansky, Alona, Stemmer-Rachamimov, Anat, Ramesh, Vijaya

    Published 2018
    Get full text Get full text
    Text
    Save to List
    Saved in:
  5. 5
    INNV-20. UTILITY OF TELEHEALTH FOR SPECIALTY NEUROFIBROMATOSIS (NF) CARE

    INNV-20. UTILITY OF TELEHEALTH FOR SPECIALTY NEUROFIBROMATOSIS (NF) CARE by Jordan, Justin, Seijo, Marlon, Merker, Vanessa, Bhadola, Shivkumar, Thalheimer, Raquel, Plotkin, Scott R

    Published 2018
    Get full text Get full text
    Text
    Save to List
    Saved in:
  6. 6
    Clinical Features of Schwannomatosis: A Retrospective Analysis of 87 Patients

    Clinical Features of Schwannomatosis: A Retrospective Analysis of 87 Patients by Merker, Vanessa L., Esparza, Sonia, Smith, Miriam J., Stemmer-Rachamimov, Anat, Plotkin, Scott R.

    Published 2012
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  7. 7
    NIMG-66. LONG-TERM FOLLOW-UP OF NEUROFIBROMATOSIS TYPE 1 PATIENTS USING WHOLE-BODY MRI DEMONSTRATES DYNAMIC CHANGES IN INTERNAL NEUROFIBROMA SIZE

    NIMG-66. LONG-TERM FOLLOW-UP OF NEUROFIBROMATOSIS TYPE 1 PATIENTS USING WHOLE-BODY MRI DEMONSTRATES DYNAMIC CHANGES IN INTERNAL NEUROFIBROMA SIZE by Ly, Ina, Thalheimer, Raquel, Cai, Wenli, Bredella, Miriam, Merker, Vanessa, Plotkin, Scott, Jordan, Justin

    Published 2019
    Get full text Get full text
    Text
    Save to List
    Saved in:
  8. 8
    Outcomes of hospitalization in pregnant women with CNS neoplasms: a population-based study

    Outcomes of hospitalization in pregnant women with CNS neoplasms: a population-based study by Terry, Anna R., Barker, Fred G., Leffert, Lisa, Bateman, Brian T., Souter, Irene, Plotkin, Scott R.

    Published 2012
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  9. 9
    Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis

    Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schw... by Merker, Vanessa L., Dai, Annie, Radtke, Heather B., Knight, Pamela, Jordan, Justin T., Plotkin, Scott R.

    Published 2018
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  10. 10
    Measuring the Effect of Cutaneous Neurofibromas on Quality of Life in Neurofibromatosis Type 1

    Measuring the Effect of Cutaneous Neurofibromas on Quality of Life in Neurofibromatosis Type 1 by Maguiness, Sheilagh, Berman, Yemima, Rubin, Nathan, Dodds, Melissa, Plotkin, Scott R., Wong, Claire, Moertel, Christopher

    Published 2021
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  11. 11
    Erlotinib for Progressive Vestibular Schwannoma in Neurofibromatosis 2 Patients

    Erlotinib for Progressive Vestibular Schwannoma in Neurofibromatosis 2 Patients by Plotkin, Scott R., Halpin, Chris, McKenna, Michael J., Loeffler, Jay S., Batchelor, Tracy T., Barker, Fred G.

    Published 2010
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  12. 12
    Effective Provider-Patient Communication of a Rare Disease Diagnosis: A Qualitative Study of People Diagnosed with Schwannomatosis

    Effective Provider-Patient Communication of a Rare Disease Diagnosis: A Qualitative Study of People Diagnosed with Schwannomatosis by Merker, Vanessa L., Plotkin, Scott R., Charns, Martin P., Meterko, Mark, Jordan, Justin T., Elwy, A. Rani

    Published 2020
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  13. 13
    Expression of SMARCB1 (INI1) mutations in familial schwannomatosis

    Expression of SMARCB1 (INI1) mutations in familial schwannomatosis by Smith, Miriam J., Walker, James A., Shen, Yiping, Stemmer-Rachamimov, Anat, Gusella, James F., Plotkin, Scott R.

    Published 2012
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  14. 14
    mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition

    mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition by Beauchamp, Roberta L., Erdin, Serkan, Witt, Luke, Jordan, Justin T., Plotkin, Scott R., Gusella, James F., Ramesh, Vijaya

    Published 2020
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  15. 15
    Awareness and agreement with neurofibromatosis care guidelines among U.S. neurofibromatosis specialists

    Awareness and agreement with neurofibromatosis care guidelines among U.S. neurofibromatosis specialists by Merker, Vanessa L., Knight, Pamela, Radtke, Heather B., Yohay, Kaleb, Ullrich, Nicole J., Plotkin, Scott R., Jordan, Justin T.

    Published 2022
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  16. 16
    Emotional functioning of patients with neurofibromatosis tumor suppressor syndrome

    Emotional functioning of patients with neurofibromatosis tumor suppressor syndrome by Wang, Daphne L., Smith, Kelly B., Esparza, Sonia, Leigh, Fawn A., Muzikansky, Alona, Park, Elyse R., Plotkin, Scott R.

    Published 2012
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  17. 17
    GENE-42. MOLECULAR AND HISTOLOGIC FEATURES OF A SERIES OF SPORADIC AND FAMILIAL SCHWANNOMAS

    GENE-42. MOLECULAR AND HISTOLOGIC FEATURES OF A SERIES OF SPORADIC AND FAMILIAL SCHWANNOMAS by Williams, Erik, Kim, James, Muzikansky, Alona, Shaw, McKenzie, Iafrate, A John, Plotkin, Scott, Suva, Mario, Stemmer-Rachamimov, Anat

    Published 2017
    Get full text Get full text
    Text
    Save to List
    Saved in:
  18. 18
    Pseudoprogression of Malignant Peripheral Nerve Sheath Tumor in Patient with Neurofibromatosis Type 1, a Case Report

    Pseudoprogression of Malignant Peripheral Nerve Sheath Tumor in Patient with Neurofibromatosis Type 1, a Case Report by Lessing, Andrés J., Cote, Gregory M., DeLaney, Thomas F., Plotkin, Scott R., Raskin, Kevin A., Lessing, Juan N.

    Published 2021
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  19. 19
    CLRM-16 PATIENT-FOCUSED DRUG DEVELOPMENT IN NEURO-ONCOLOGY: A PILOT STUDY OF QUALITATIVE PATIENT INTERVIEWS EMBEDDED WITHIN A NEUROFIBROMATOSIS 2 CLINICAL TRIAL

    CLRM-16 PATIENT-FOCUSED DRUG DEVELOPMENT IN NEURO-ONCOLOGY: A PILOT STUDY OF QUALITATIVE PATIENT INTERVIEWS EMBEDDED WITHIN A NEUROFIBROMATOSIS 2 CLINICAL TRIAL by Merker, Vanessa, Von Imhof, Liesel, Park, Elyse, Babovic-Vuksanovic, Dusica, NghiemPhu, PhiOanh [Leia], Yohay, Kaleb, Plotkin, Scott

    Published 2022
    Get full text Get full text
    Text
    Save to List
    Saved in:
  20. 20
    Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth

    Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth by James, Marianne F., Lelke, Johanna M., MacCollin, Mia, Plotkin, Scott R., Stemmer-Rachamimov, Anat O., Ramesh, Vijaya, Gusella, James F.

    Published 2007
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:

Search Tools: